Login to Your Account



Penwest Funding: $32.8M For Two Lead Compounds

By Randall Osborne


Monday, December 13, 2004
With a protocol approved by the FDA and a trial under way with its lead product, delivery firm Penwest Pharmaceuticals Co. will net about $32.8 million through a private placement of about 3.1 million shares of common stock at $11.20 per share. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription